Breakthrough Biofilm Tech for Animal Health

As the demand for advanced veterinary care grows, practical solutions are needed to address biofilm-related infections and the rise of antimicrobial resistance. We developed a method that directly targets biofilms—protective layers formed by harmful microbes—offering a more effective way to treat persistent conditions like oral and ear infections in pets. This technology not only improves treatment outcomes but also reduces the need for frequent care. With a strong product pipeline and expanding market potential, it’s poised to make a significant impact on animal healthcare.

Addressing a Key Challenge in Veterinary Medicine

Biofilms are one of the biggest obstacles to treating infections. These microbial shields make infections harder to resolve with traditional treatments. Our product, GingiGuard, disrupts these biofilms, helping to treat conditions like gum disease without the need for daily intervention. This method addresses the growing issue of antimicrobial resistance by reducing the overuse of antibiotics, contributing to long-term, sustainable animal healthcare.

Proven Safety and Effectiveness

GingiGuard has shown its ability to effectively disrupt biofilms in laboratory and animal studies, targeting microbes like MRSA, Candida, and Porphyromonas, which are common in oral infections. By selectively blocking key microbes, the product breaks down harmful plaque and prevents its reformation.

The product has also been proven safe. In one case study, a Belgian Malinois with advanced periodontal disease saw improvement after a single application, with the treatment remaining active for over 30 days.

Competitive Pricing in the Market

Compared to existing solutions that require frequent applications, GingiGuard is designed to deliver long-lasting effects with much less frequent use. The final cost to consumers will be competitive with current treatments but with the added benefit of significantly reduced maintenance and better overall results. This positions it as a high-value alternative in the veterinary care market.

Expanding the Product Line

Beyond oral care, our biofilm-disrupting technology is being developed to treat ear infections, wounds, and eye conditions in companion animals. Clinical trials are underway for equine eye fungal disease and mare infertility, expanding our reach into other segments of veterinary medicine.

A High-Value Investment Opportunity

With three patents pending and a clear path for FDA approval in the animal health market, we offer a strong investment opportunity. Our lean R&D approach and focused regulatory strategy allow us to achieve high returns across multiple areas of animal healthcare.

We are actively seeking partnerships with companies that can help us promote and distribute our products. By partnering with an established company in the veterinary or pharmaceutical space, we can quickly scale and deliver these products to market, leveraging our first-mover advantage in biofilm treatment.